Healthcare Holding B.V. Gilde Sells 2,095 Shares of Shoulder Innovations (NYSE:SI) Stock

Shoulder Innovations, Inc. (NYSE:SI) major shareholder Healthcare Holding B.V. Gilde sold 2,095 shares of the business’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $22.60, for a total transaction of $47,347.00. Following the sale, the insider directly owned 2,212,207 shares of the company’s stock, valued at approximately $49,995,878.20. This represents a 0.09% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Healthcare Holding B.V. Gilde also recently made the following trade(s):

• On Wednesday, August 5th, Healthcare Holding B.V. Gilde sold 7,338 shares of Shoulder Innovations stock. The stock was sold at an average price of $22.64, for a total transaction of $166,132.32.
• On Tuesday, August 4th, Healthcare Holding B.V. Gilde sold 99,812 shares of Shoulder Innovations stock. The shares were sold at an average price of $22.77, for a total value of $2,272,719.24.
• On Monday, August 3rd, Healthcare Holding B.V. Gilde sold 10,751 shares of Shoulder Innovations stock. The shares were sold at an average price of $22.71, for a total value of $244,155.21.
• On Friday, July 31st, Healthcare Holding B.V. Gilde sold 20,034 shares of Shoulder Innovations stock. The stock was sold at an average price of $22.73, for a total value of $455,372.82.
• On Thursday, July 30th, Healthcare Holding B.V. Gilde sold 28,245 shares of Shoulder Innovations stock. The shares were sold at an average price of $23.36, for a total value of $659,803.20.

Shoulder Innovations Stock Performance

NYSE SI traded down $1.89 during trading hours on Friday, hitting $20.54. The company had a trading volume of 286,871 shares, compared to its average volume of 93,468. Shoulder Innovations, Inc. has a fifty-two week low of $10.92 and a fifty-two week high of $24.59. The company has a quick ratio of 10.04, a current ratio of 11.81 and a debt-to-equity ratio of 0.11. The business has a fifty day simple moving average of $19.79 and a 200-day simple moving average of $16.04. The firm has a market cap of $426.06 million and a P/E ratio of -0.12.

Shoulder Innovations (NYSE:SI) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.03. Shoulder Innovations had a negative net margin of 81.78% and a negative return on equity of 35.11%. The business had revenue of $16.71 million during the quarter. Equities analysts predict that Shoulder Innovations, Inc. will post -1.67 EPS for the current year.

More Shoulder Innovations News

Here are the key news stories impacting Shoulder Innovations this week:

• Positive Sentiment: Analysts raised their targets: Piper Sandler reaffirmed its “overweight” rating and lifted its price target from $19 to $25, while BTIG Research raised its target from $24 to $26 and initiated a “buy” rating. These targets imply meaningful upside and may support investor sentiment. Benzinga analyst rating updates
• Positive Sentiment: Revenue growth remained strong: Second-quarter revenue increased approximately 56% year over year to $17.2 million, slightly exceeding estimates. Gross profit rose about 60%, indicating continued demand and improving product economics. Shoulder Innovations Q2 2026 earnings summary
• Positive Sentiment: Full-year guidance was raised: SI forecast fiscal-year revenue of $67 million to $69 million, broadly in line with the roughly $67.1 million consensus estimate. Management also highlighted 60% first-half revenue growth. Shoulder Innovations raises full-year outlook
• Neutral Sentiment: Liquidity appears adequate but is declining: The company ended the quarter with $24.5 million in cash and used $7.4 million in operating activities and $2.2 million in capital expenditures. Investors will likely monitor whether revenue growth can lead to improved cash generation.
• Negative Sentiment: Profitability remains a concern: SI reported an operating loss of about $10 million, a net loss of approximately $10.2 million, and diluted EPS near negative $0.49, missing some estimates. The company remains deeply unprofitable, increasing valuation sensitivity. Shoulder Innovations quarterly results
• Negative Sentiment: Major-holder selling may weigh on sentiment: Gilde Healthcare sold more than 110,000 shares in early August for roughly $2.5 million. Although it retains a substantial stake, the sales can raise concerns about near-term supply and insider conviction. Gilde Healthcare insider sale

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. BTIG Research raised their price target on shares of Shoulder Innovations from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Friday. Weiss Ratings raised Shoulder Innovations from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday. Piper Sandler restated an “overweight” rating and issued a $25.00 target price (up from $19.00) on shares of Shoulder Innovations in a research report on Friday. Finally, UBS Group initiated coverage on Shoulder Innovations in a research note on Tuesday, July 28th. They set a “buy” rating and a $27.00 target price on the stock. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Shoulder Innovations currently has a consensus rating of “Moderate Buy” and an average target price of $23.33.

Institutional Trading of Shoulder Innovations

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Deerfield Management Company L.P. acquired a new stake in shares of Shoulder Innovations in the 3rd quarter worth approximately $6,056,000. Alyeska Investment Group L.P. acquired a new position in shares of Shoulder Innovations during the third quarter valued at approximately $5,667,000. Vanguard Group Inc. bought a new stake in Shoulder Innovations during the third quarter worth approximately $1,836,000. Roubaix Capital LLC lifted its position in Shoulder Innovations by 61.9% in the first quarter. Roubaix Capital LLC now owns 257,121 shares of the company’s stock worth $3,736,000 after purchasing an additional 98,305 shares during the period. Finally, Millennium Management LLC acquired a new stake in Shoulder Innovations in the fourth quarter worth approximately $1,316,000.

About Shoulder Innovations

Shoulder Innovations (NYSE:SI) is a medical device company focused on the design, development and commercialization of shoulder implant systems and related surgical instruments for orthopedic surgery. The company’s product portfolio includes modular shoulder prostheses, humeral and glenoid components, and instrumentation kits designed to facilitate both primary and revision shoulder arthroplasty procedures. Emphasizing a patient-centric approach, Shoulder Innovations works to offer implant solutions that aim to restore mobility and reduce post-operative complications.

In addition to its core implant offerings, Shoulder Innovations provides comprehensive clinical support and training programs for surgeons and operating room teams.